Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nadolol
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : CincyTech
Deal Size : $7.7 million
Deal Type : Series B Financing
Invirsa Completes $7.7M Series B Financing
Details : The net financing will be used in advancing Invirsa's lead product candidate, INV-102, derived from a naturally occurring small molecule, in a series of Phase 2 studies in conditions including acute infectious keratoconjunctivitis, dry eye disease, and F...
Brand Name : INV-102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Nadolol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : CincyTech
Deal Size : $7.7 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?